Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
Authors:
- Olga GoronkovaOGOlga Goronkova
- Galina NovichkovaGNGalina Novichkova
- Tatiana SalimovaTSTatiana Salimova
- Irina KalininaIKIrina Kalinina
- Ulyana PetrovaUPUlyana Petrova
- Kristina AntonovaKAKristina Antonova
- Maria SadovskayaMSMaria Sadovskaya
- Elena SuntsovaESElena Suntsova
- Dmitry EvseevDEDmitry Evseev
- Victor MatveevVMVictor Matveev
- Dmitry VenyovDVDmitry Venyov
Open Access
- 16 March 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (6) , 953-962
Abstract
We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(−) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(−) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.Keywords
This publication has 30 references indexed in Scilit:
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaNew England Journal of Medicine, 2012
- Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working PartyBlood, 2012
- Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic AnemiaNew England Journal of Medicine, 2011
- A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow TransplantationBlood, 2011
- Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysisHaematologica, 2009
- Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor AgonistStem Cells, 2009
- Long-Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin and CyclosporineThe Journal of Pediatrics, 2008
- Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long‐term observation follow‐upBritish Journal of Haematology, 2007
- Immunosuppressive therapy for acquired severe aplastic anemia (SAA): A prospective comparison of four different regimensExperimental Hematology, 2006
- CRITERIA FOR SEVERE APLASTIC ANAEMIAThe Lancet, 1988